Deep Basin Capital’s Core Laboratories CLB Stock Holding History

Deep Basin Capital’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-315,170	Closed	-$6.4M	–	49
2020 Q2	$6.4M	Buy	+315,170	New	+$5.65M	0.93%	38

Other funds holding CLB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deep Basin Capital's CLB Position: Q3 2020 in Review

Deep Basin Capital sold out of Core Laboratories (CLB) in Q3 2020, closing a stake of 315,170 shares — an estimated $6.4M sold.

Deep Basin Capital first reported a position in CLB in Q2 2020 and held it in 1 quarter. The position peaked at $6.4M in Q2 2020. 187 funds tracked by Wall St. Rank hold CLB as of Q3 2020.

Deep Basin Capital reported no remaining Core Laboratories position as of Q3 2020 after selling out during the quarter.
Deep Basin Capital sold 315,170 Core Laboratories shares in Q3 2020, an estimated $6.4M.
Deep Basin Capital first reported a position in Core Laboratories in Q2 2020 and held it in 1 quarter.
Deep Basin Capital's Core Laboratories position peaked at $6.4M in Q2 2020.
187 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2020.

Based on Deep Basin Capital's 13F filing for Q3 2020, filed 13 Nov 2020.